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1  | INTRODUC TION
Systemic capillary leak syndrome (SCLS) is an extremely rare and po‐
tentially fatal disorder of unknown aetiology. SCLS is characterized 
by recurrent, spontaneous attacks of hypovolemic shock and ana‐
sarca due to sudden and massive leakage of intravascular fluids and 
proteins into peripheral tissues. Termed “Clarkson disease” in 1960 
for its discoverer, SCLS is diagnosed based on a unique constella‐
tion of signs and symptoms including severe hypotension, elevated 
haematocrit resulting from hemoconcentration and hypoalbumin‐
emia due to leakage from the intravascular space.1 Patients are fre‐
quently misdiagnosed initially with other conditions such as sepsis 
and treated with aggressive intravenous fluid resuscitation. Such 
therapy induces massive “third spacing” of fluids and solutes into pe‐
ripheral tissues and development of compartment syndromes, which 
may require fasciotomies. There are no specific treatments for acute 
flares of SCLS beyond haemodynamic stabilization, nor is there cu‐
rative therapy.
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Abstract
Systemic capillary leak syndrome (SCLS; Clarkson disease) is a rare orphan disor‐
der characterized by transient yet recurrent episodes of hypotension and periph‐
eral oedema due to diffuse vascular leakage of fluids and proteins into soft tissues. 
Humoral	mediators,	cellular	responses	and	genetic	features	accounting	for	the	clini‐
cal	phenotype	of	SCLS	are	virtually	unknown.	Here,	we	searched	for	factors	altered	
in acute SCLS plasma relative to matched convalescent samples using multiplexed 
aptamer‐based proteomic screening. Relative amounts of 612 proteins were changed 
greater	than	twofold	and	81	proteins	were	changed	at	 least	 threefold.	Among	the	
most enriched proteins in acute SCLS plasma were neutrophil granule components in‐
cluding bactericidal permeability inducing protein, myeloperoxidase and matrix met‐
alloproteinase	8.	Neutrophils	 isolated	from	blood	of	subjects	with	SCLS	or	healthy	
controls	responded	similarly	to	routine	pro‐inflammatory	mediators.	However,	acute	
SCLS	sera	activated	neutrophils	relative	to	remission	sera.	Activated	neutrophil	su‐
pernatants increased permeability of endothelial cells from both controls and SCLS 
subjects equivalently. Our results suggest systemic neutrophil degranulation during 
SCLS acute flares, which may contribute to the clinical manifestations of acute vas‐
cular leak.
K E Y W O R D S
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Specific aetiological factors and pathways contributing the pro‐
found vascular barrier breakdown characteristic of acute SCLS flares 
are	 unknown.	 Although	 more	 than	 80%	 of	 SCLS	 patients	 have	 a	
monoclonal gammopathy of unknown significance, there is no direct 
or indirect evidence that the monoclonal IgG has any role in disease 
pathogenesis.2 In our studies of more than 65 patients with a confirmed 
diagnosis of SCLS, we found that several inflammatory cytokines (eg 
TNFα,	CCL2,	CXCL10)	and	mediators	of	vascular	permeability	(VEGF,	
Angpt‐2)	were	significantly	elevated	in	sera	from	patients	during	acute	
episodes compared to convalescent intervals.2,3 Treatment of normal 
vascular endothelial cells (ECs) with acute but not remission sera from 
these patients disrupted vascular integrity through mechanisms in‐
cluding internalization of VE‐cadherin and actin stress fibre formation.
In order to broaden our search for mediators unique to SCLS and/
or uncover a signature of humoral factors characteristic of acute at‐
tacks,	we	used	the	slow‐off	rate	modified	aptamer	(SOMA)scan	plat‐
form, an aptamer‐based highly multiplexed proteomic assay capable 
of detecting more than 1300 protein analytes simultaneously across 
the whole dynamic range from only a small volume of plasma with 
high sensitivity and specificity.4	The	SOMAscan	approach	uncovered	
more than 600 proteins, whose relative amounts were increased more 
than twofold in acute plasma relative to matched baseline plasma 
from	 the	 same	 patients.	 Most	 notably,	 several	 neutrophil	 granule	
proteins	were	profoundly	elevated	in	acute	SCLS	plasma.	Acute	but	
not remission sera from SCLS patients activated neutrophils, and su‐
pernatants from activated neutrophils induced hyperpermeability of 
ECs. These results suggest that activated and/or degranulated neu‐
trophils contribute to the pathogenesis of acute SCLS.
2  | MATERIAL S AND METHODS
2.1 | Subjects
Patients were diagnosed with SCLS according to established criteria, 
specifically a history of one or more transient episodes of hypotension, 
elevated haematocrit and hypoalbuminemia.5,6 Patients were seen at 
the	Clinical	 Center	 of	 the	National	 Institutes	 of	Health.	Written	 in‐
formed consent was obtained from each patient and the study protocol 
(I‐0184)	conformed	to	the	ethical	guidelines	of	the	2008	Declaration	
of	Helsinki,	having	been	approved	by	the	Institutional	Review	Board	of	
the	National	Institute	of	Allergy	and	Infectious	Diseases	of	NIH.	EDTA	
plasma and sera were collected and stored from both remission and ac‐
tive	disease	intervals	where	available.	Neutrophils	were	available	only	
from	asymptomatic	patients.	Anonymized	age‐,	sex‐	and	race‐matched	
blood	 from	 healthy	 volunteers	 were	 obtained	 from	 the	 NIH	 Blood	
Bank for neutrophil isolation and used as controls.
2.2 | Cells and reagents
Human	microvascular	endothelial	cells	(HMVECs)	and	the	culture	me‐
dium	EGM2	were	purchased	from	Lonza.	Blood	outgrowth	endothelial	
cells (BOECs) were generated and cultured as described previously.7 
Lipopolysaccharide	(LPS),	cytochalasin	B	and	N‐formyl‐Met‐Leu‐Phe	
(fMLP)	 were	 obtained	 from	 Sigma‐Aldrich.	 Human	 recombinant	
VEGFA‐165	and	TNFα	were	from	PeproTech.	Antibodies	anti‐human	
CD11b/BV786,	CD16/APC	and	CD62L/PE	were	from	Biolegend.
2.3 | SOMAscan and ELISA
Nine	pairs	of	EDTA‐plasma	samples	obtained	at	or	near	the	onset	of	
an acute SCLS crisis and from the same patient during a convalescent 
interval	were	 analysed	 using	 the	 SOMAscan	Assay	Kit	 for	 human	
plasma 1.3k V3.2 (SomaLogic, Inc, cat.#900‐00011) according to the 
standard	protocol	for	EDTA	plasma	from	the	manufacturer's	and	as	
described previously.8	Five	pooled	human	plasma	controls	and	one	
buffer control were run on the same plate with the test samples for 
calibration	 and	 normalization.	 Median	 normalization	 and	 calibra‐
tion of the data were performed according to the standard quality 
control	protocols	at	SomaLogic.	All	samples	passed	the	established	
quality	control	criteria.	SOMAscan	data	were	analysed	using	Partek	
Genomics Suite and statistical significance determined using two‐
way	ANOVA.	Proteins	enriched	in	acute	vs remission plasma at least 
threefold (P	<	0.01)	were	used	to	generate	the	Heatmap.	Functional	
enrichment	 was	 determined	 using	 Ingenuity	 Pathway	 Analysis	
software	 (Qiagen)	using	Fisher's	Exact	with	FDR	multiple	 test	cor‐
rection.	 ELISAs	 for	 elastase,	 myeloperoxidase	 (MPO),	 α‐defensin, 
lactoferrin	and	MMP‐9	were	performed	according	to	the	manufac‐
turer's	 instructions	 (Cayman	Chemical	 for	MPO;	R&D	Systems	 for	
the remainder).
2.4 | Neutrophil isolation
Neutrophils	were	 isolated	 from	whole	blood	using	Hypaque	Ficoll	
separation. Briefly, 1:1 PBS diluted blood was added onto the top 
of	Ficoll	 (lymphocyte	separation	medium,	MP	Biomedicals),	centri‐
fuged at 800x g at room temperature for 20 minutes with the brake 
off.	 Neutrophils	 were	 retrieved	 from	 the	 bottom	 layer	 containing	
RBCs.	 After	 RBC	 lysis	 using	 ACK	 lysing	 buffer,	 cell	 pellets	 were	
washed	twice	in	PBS.	Neutrophil	purity	was	routinely	~95%	based	
on surface marker expression (CD16+, CD3−/CD19−) as determined 
by flow cytometry.
2.5 | Neutrophil activation/degranulation
For	analysis	of	neutrophil	activation,	freshly	isolated	neutrophils	were	
incubated with buffer or stimuli in culture medium at 37°C for the in‐
dicated time periods, followed by termination of the reaction by ad‐
dition of ice‐cold PBS. Cells were then stained with Live/Dead violet 
(ThermoFisher),	 washed	 once	 and	 stained	with	 anti‐human	CD11b/
BV785,	CD16/APC	and	CD62L/PE.	The	samples	were	then	analysed	
using	an	LSRII	 flow	cytometer	and	the	data	processed	using	FlowJo	
software	 (BD	 BioSciences).	 MPO	 levels	 were	 determined	 by	 ELISA	
(Cayman Chemical). Briefly, purified neutrophils were incubated with 
fMLP	(100	nmol/L)	 for	15	minutes	 in	complete	RPMI	at	37°C	 in	the	
presence of cytochalasin B (10 mol/L). Supernatants were collected 
and	analysed	by	ELISA	according	to	the	manufacturer's	instructions.
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2.6 | Endothelial permeability measurements
An	electric	cell‐substrate	impedance	sensing	(ECIS)	assay	was	used	
to assess endothelial barrier function. Electrical resistance was 
measured	across	endothelial	monolayers	at	4,000	Hz	using	the	ECIS	
Zθ	apparatus	(Applied	BioPhysics)	as	described	previously.2 Briefly, 
ECs	were	serum	starved	in	endothelial	basal	medium	(EBM2,	Lonza)	
plus	 0.2%	BSA	 for	 5	 hours	 followed	 by	 addition	 of	 test	 reagents.	
Resistance was recorded over a period of 20 hours. Each condition 
was measured in duplicate in a single experiment and averaged. 
Absolute	resistance	values	were	normalized	by	subtracting	the	re‐
sistance at time zero (pre‐treatment); the maximal change in resist‐
ance was calculated as percentage change over time zero.
2.7 | Statistical analysis
ELISA	and	flow	cytometric	data	were	analysed	with	GraphPad	Prism	
7	software	package.	Data	were	analysed	by	two‐way	ANOVA	with	
multiple corrections testing, and non‐parametric tests were used for 
flow	data	analysis	 (Mann‐Whitney	 test	 for	analysis	of	 two	groups;	
Kruskal‐Wallis	 for	analysis	of	multiple	groups).	P < 0.05 were con‐
sidered significant.
3  | RESULTS
3.1 | Proteomic profile of acute SCLS plasma
Although	the	clinical	symptoms	of	acute	SCLS	crises,	including	hemo‐
dynamic collapse and anasarca, are quite dramatic, patients are typically 
asymptomatic	in	between	episodes.	Although	SCLS	flares	may	occur	in	
the absence of obvious triggers, recent survey studies suggest that in‐
fections	(typically	upper	respiratory)	precede	SCLS	attacks	in	35%‐50%	
of adult patients.1,9 These findings suggest that infection‐related inflam‐
matory mediators may induce vascular leakage in some patients. Indeed, 
in limited prior screening of acute SCLS sera, we found elevated levels of 
pro‐inflammatory	mediators	including	TNFα, CXCL10, CCL2 and IL‐8.2,3 
To	more	 fully	 probe	 the	 SCLS	 proteome,	 we	 performed	 SOMAscan	
profiling of 1305 proteins in nine matched plasma samples obtained by 
venipuncture during acute or convalescent intervals. The characteris‐
tics of these patients are described in Table 1. This assay identified 612 
proteins, whose relative amounts were changed at least twofold in epi‐
sodic plasma relative to baseline (P < 0.05) (full list in Table S1), and all 
but three of them were increased. Eighty‐one proteins were increased 
at least threefold in episodic plasma (P	<	0.001)	(Figure	1A).	With	one	
exception, the protein profile of episodic and baseline samples clustered 
with one another. Consistent with previous studies of our entire SCLS 
cohort, several cytokines and vascular permeability mediators including 
CCL2, CXCL10, IL‐12, IL‐1β,	TNFα,	adrenomedullin,	Angpt‐2	and	VEGFA	
were significantly elevated in episodic plasma compared to remission 
plasma (Table S2).2,3,10	We	also	discovered	enrichment	of	several	pro‐
teins not previously associated with SCLS including surfactant protein 
D	S(P‐D),	capping	actin	protein	(CAPG),	chymase,	allograft	inflammatory	
factor	(AIF1),	the	TNFα	superfamily	member	LIGHT	and	the	stressorin	
IL‐16	 (Table	 2).	 We	 analysed	 functional	 enrichment	 using	 Ingenuity	
pathway	 analysis.	 In	 the	 category	of	 “Disease	&	Biological	 Function”,	
“Inflammatory response” was the statistically most significant category 
(P = 10−15)	(Figure	1B);	“Upstream	Regulators”	enriched	in	acute	SCLS	
samples included several pro‐inflammatory mediators such as LPS, 
IL‐1β	 and	 TNFα (all P < 10−6)	 (Figure	 1C).	 Finally,	 the	 top	 “Canonical	
Pathways” implicated in acute SCLS were IL‐8 and glucocorticoid signal‐
ling (P = 10−6)	(Figure	1D).
3.2 | Neutrophil activation signature in SCLS 
disease flares
Among	 the	 proteins	 that	 were	 increased	 the	most	 in	 acute	 SCLS	
plasma were neutrophil granule components bactericidal perme‐
ability increasing protein (BPI) (19.5‐fold), matrix metalloproteinase 
8	(MMP8,	7.9‐fold)	and	MMP9	(4.5‐fold)	 (Table	3).	As	noted	above	
functionally enriched pathways in acute samples included signal‐
ling involving IL‐8, a well‐known neutrophil chemoattractant, and 
LPS, which also activates neutrophils.11 Given these findings, we 
Sample # Sex
Age at  
diagnosis #Episodes Complications
Current 
treatment
1 M 63 >10 None IVIG
2 F 40 4 CS, neuropathy IVIG
3 M 48 >20 CS, neuropathy,  
thrombosis, GI infarct
IVIG
4 M 48 2 None IVIG
5 M 46 >10 None IVIG
6 M 43 11 CS IVIG
7 M 68 >10 CS IVIG
8 F 48 2 (+chronic) Diarrhoea, vomiting, 
wasting
None	
(deceased)
9 F 37 2 Cardiac tamponade IVIG
Abbreviation:	CS,	compartment	syndrome;	SCLS,	systemic	capillary	leak	syndrome
TA B L E  1   Characteristics of SCLS 
patients
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F I G U R E  1  Proteomic	profiling	of	systemic	capillary	leak	syndrome	(SCLS)	plasma.	Nine	pairs	of	matched	acute‐remission	plasma	from	
SCLS	patients	were	analysed	using	SOMAscan.	(A),	Heatmap	representation	of	relative	protein	amounts.	(B‐D),	Disease	associations	
determined by Ingenuity pathway analysis and represented by P‐values	(Fisher's	exact	test)
A
B C D
Protein P‐value
Fold change (Epi/
Bas)
Functional annotation 
(Ref)
Surfactant protein D 
(SP‐D)
0.003019 13.4 Immunomodulatory (22)
Capping actin protein 
(CAPG)
0.001301 6.8 Gelsolin‐related (actin 
binding protein); inflam‐
mation (23)
Chymase 0.000384 6.56 Mast	cell‐derived	(24)
Allograft	inflammatory	
factor 1
0.000172 4.36 Actin‐bindin	protein;	pro‐
inflammatory (25)
LIGHT 0.001306 3.99 TNFα superfamily (26)
IL‐16 0.000697 3.05 Stressorin (27)
TA B L E  2  Novel	systemic	capillary	leak	
syndrome‐associated proteins
     |  5123XIE Et al.
hypothesized that neutrophil degranulation and activation may 
contribute to SCLS flares. To confirm the presence of systemic neu‐
trophil degranulation in SCLS, we measured levels of granule compo‐
nents	in	the	same	plasma	samples	used	for	SOMAscan	screening	by	
quantitative	ELISA.	Contents	of	primary	granules	including	elastase,	
MPO	and	α‐defensin, secondary granules (lactoferrin) and tertiary 
granules	 (MMP‐9)	 were	 significantly	 increased	 in	 episodic	 SCLS	
plasma	compared	to	baseline	in	all	patients	(Figure	2A‐E),	confirming	
the	SOMAscan‐derived	data.	Although	total	neutrophil	counts	were	
not available from the date the acute plasma were drawn, absolute 
neutrophilia is not a consistent feature of acute SCLS attacks in our 
cohort as a whole although total white blood cell counts may be el‐
evated due to infection and/or hemoconcentration. Indeed, protein 
extravasation and reduced blood volume may confound interpreta‐
tion of plasma protein quantities during an SCLS flare. To evaluate 
the	contribution	of	such	factors,	we	normalized	raw	SOMAScan	val‐
ues	for	 (MPO,	molecular	weight	150	kDa)	by	those	for	proteins	of	
comparable size, whose relative values were unchanged in matched 
acute	 and	 remission	 samples.	 MPO	 corrected	 for	 either	 NrCAM	
(molecular	weight	[mw]	140	kDa)	or	MET	(mw	145	kDa)	values	were	
similar	 to	 uncorrected	 values	 (Figure	 S1).	 Thus,	 we	 conclude	 that	
hemoconcentration alone is unlikely to account for the increased 
MPO	in	acute	SCLS	plasma	relative	to	convalescence.	 Instead,	our	
findings suggested that widespread neutrophil degranulation occurs 
in circulation during SCLS crises.
3.3 | Intrinsic neutrophil function in SCLS
We	next	determined	whether	neutrophils	from	SCLS	patients	are	
intrinsically hyper‐responsive to inflammatory stimuli, which could 
account	for	the	increased	granule	components	in	acute	plasma.	We	
first measured neutrophil oxidative burst using a dihydrorhodamine 
assay. In response to phorbol myristate acetate stimulation, neu‐
trophils from SCLS subjects yielded an average stimulation index 
of 187.7 ± 2.97, well within the normal range of the testing clinical 
laboratory ([115‐291], n = 3), indicating that the neutrophil oxida‐
tive	burst	 is	 intact	 in	SCLS.	We	next	measured	degranulation	by	
quantifying	MPO	secretion.	Amounts	of	MPO	released	following	
fMLP	 stimulation	of	neutrophils	 from	SCLS	 subjects	 and	healthy	
controls	were	indistinguishable	from	one	another	(Figure	3A).	We	
also assessed neutrophil activation by quantifying surface marker 
expression	 using	 flow	 cytometry.	 Activated	 neutrophils	 upregu‐
late CD11b while shedding other membrane‐associated proteins 
including CD62L (L‐selectin) and CD16. Baseline expression of nu‐
merous surface markers was comparable in untouched neutrophils 
from whole blood of SCLS patients and controls as assessed by flow 
cytometry, including granulocyte activation markers 31D8, CD63 
and CD62L, β2‐integrins	 and	 Fc	 receptors	 (Figure	 S2).	 Likewise,	
stimulation of purified neutrophils with several proinflammatory 
mediators	 including	 fMLP,	 TNFα and LPS induced a comparable 
pattern of activation marker expression in neutrophils isolated 
from peripheral blood of healthy donors and SCLS subjects dur‐
ing	disease‐free	intervals	(Figure	3B‐D).	These	results	indicate	that	
neutrophils from SCLS subjects retain the capacity to degranulate 
and release reactive oxygen species (ROS) in response to pro‐in‐
flammatory stimuli.
3.4 | Acute SCLS sera induce neutrophil activation
A	subpopulation	of	highly	activated	neutrophils	(CD62LdimCD16bright) 
is recruited to the circulation from bone marrow in response to acute 
systemic inflammation associated with sepsis and acute trauma, 
among others.12,13 Given the link between SCLS episodes and in‐
fection, and the presence of pro‐inflammatory cytokines in acute 
SCLS sera, we hypothesized that SCLS sera and/or plasma activate 
neutrophils. To investigate this, we analysed surface marker expres‐
sion on purified neutrophils from healthy donors incubated with 
various sera by flow cytometry, as the availability of plasma was 
limited. Treatment of neutrophils with acute SCLS sera significantly 
increased the activated (CD16bright/CD62Ldim) subpopulation, with 
a concomitant decrease in the CD16bright/CD62Lbright (quiescent) 
subset, compared to cells treated with matched remission sera. 
(Figure	 4A‐D).	 This	 result	 suggests	 that	 SCLS	 serum	 components	
constrained to acute disease flares activate neutrophils, which in 
turn could account for the increase in granule components in acute 
SCLS plasma relative to that from asymptomatic individuals.
Protein p‐value
Fold change 
(Epi/Bas) Granules
Bactericidal permeability 
increasing protein (BPI)
1.65E‐05 19.52 Azurophilic/primary
Myeloperoxidase	(MPO) 0.0009012 3.07 Azurophilic/primary
Cathepsin G 0.0011997 2.80 Azurophilic/primary
Matrix	Metalloproteinase	8	
(MMP8)
0.0190632 7.93 Specific/secondary
Gelatinase	(MMP9) 0.0004257 4.54 Tertiary
MMP1 0.0023533 2.62 Tertiary
MMP13 0.0057115 1.66 Tertiary
Significantly	enriched	neutrophil‐associated	proteins	identified	by	SOMAscan	are	listed	in	the	
table along with their granule locations.
TA B L E  3  Neutrophil	granule‐
associated proteins in acute systemic 
capillary leak syndrome sera
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3.5 | Neutrophil degranulation and vascular 
barrier integrity
We	 tested	 the	 effects	 of	 neutrophil	 granule	 contents	on	 endothe‐
lial	 barrier	 function.	 First,	 we	 stimulated	 neutrophils	 isolated	 from	
healthy	donors	with	medium	alone	or	fMLP.	We	confirmed	neutrophil	
degranulation	by	MPO	assay	(Figure	S3A).	We	then	treated	ECs	with	
supernatants from the activated neutrophils and measured transen‐
dothelial electrical resistance (TER) across monolayers in real time. 
fMLP‐stimulated	neutrophil	supernatants	from	two	separate	donors	
F I G U R E  2   Levels of neutrophil 
granule constituents in systemic capillary 
leak	syndrome	plasma.	(A‐E),	Levels	
of the indicated neutrophil granule 
components were determined in matched 
acute‐remission plasma samples used in 
SOMAscan	screening	by	ELISA
F I G U R E  3  Responses	of	neutrophils	from	systemic	capillary	leak	syndrome	(SCLS)	subjects	to	pro‐inflammatory	mediators.	Neutrophils	
were	isolated	from	whole	blood	and	incubated	left	untreated	(no	treatment,	NT)	or	treated	with	fMLP	for	15	minutes	in	the	presence	
of	cytochalasin	B.	(A),	myeloperoxidase	(MPO)	released	was	measured	by	ELISA,	and	the	data	are	expressed	as	the	fold	change	in	MPO	
compared	to	unstimulated	cells	(mean	±	SEM).	(B‐D),	Purified	neutrophils	were	not	treated	(NT)	or	exposed	to	Lipopolysaccharide	(LPS),	
fMLP	or	TNFα for one hour. Cells were immunostained with antibodies against the indicated markers and surface expression analysed by 
flow	cytometry.	Data	are	expressed	as	geometric	mean	florescence	intensity	(GMFI)	(mean	±	SEM);	*P	<	0.05,	Mann‐Whitney	u test
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led	to	decreased	TER	(ie	increased	permeability)	of	HMVECs,	while	
the resistance of cells exposed to medium alone remained relatively 
constant	over	a	period	of	10	hours	(Figure	S3B).	We	next	determined	
the effects of degranulated neutrophil supernatants on ECs isolated 
and expanded from peripheral blood of SCLS patients or healthy con‐
trols BOECs.7 The activated neutrophil supernatants reduced TER 
in	a	pattern	similar	to	commercially	supplied	HMVECs	(Figure	5A,B).	
However,	 the	maximal	decrease	 in	 resistance	 in	BOECs	 from	SCLS	
subjects and controls was equivalent at both early (30 minutes) and 
later (15 hours) time points. Thus, although neutrophil granule con‐
stituents exert permeability‐inducing effects on ECs, our data do not 
suggest hypersensitivity of SCLS ECs to this stimulus.
4  | DISCUSSION
From	our	proteomic	screening	study	of	SCLS	plasma,	we	discovered	
that	neutrophils	are	activated	during	SCLS	disease	flares.	Neutrophil	
granule contents (primary, secondary and tertiary granules), in‐
cluding	MPO,	BPI,	Cathepsin	G,	gelatinase	and	collagenases,	were	
increased in acute plasma relative to baseline, indicating systemic 
neutrophil	degranulation.	Hemoconcentration	and	protein	extrava‐
sation are confounding factors for the interpretation of changes in 
levels of plasma proteins during an SCLS flare. The degree of hemo‐
concentration	in	a	typical	SCLS	episode	is	50%‐80%,	as	indicated	by	
the mean change in hematocrit. In comparison, levels of (BPI, mw 
25	kDa),	 the	 top‐ranked	protein	 from	the	SOMAScan	screen,	 rose	
nearly	 2000%	 in	 acute	 plasma	 relative	 to	 matched	 convalescent	
plasma.	As	early	as	1977,	tracking	studies	of	proteins	of	varying	mo‐
lecular weights in SCLS sera during flares determined that although 
albumin	(mw	62	kDa)	 levels	decreased	by	30%‐50%	during	an	epi‐
sode,	C1	(mw	200	KDa)	decreased	only	10%	and	IgM	(mw	900	kDa)	
levels rose in direct proportion to the increase in hematocrit.14 Thus, 
proteins up to 900 kDa may extravasate during episodes of SCLS. 
SOMA	screening	revealed	that	MPO	(mw	150	kDa)	levels	increased	
more than threefold in acute sera relative to baseline, whereas sev‐
eral unrelated proteins of similar size were not elevated in the same 
samples	(eg	CHRDL	[150	kDa],	1.01‐fold	change	in	basal	vs episodic 
sera;	NrCAM	[140	kDa],	−1.00‐fold;	MET	[145	kDa],	1.003‐fold).	In	
addition,	SOMAScan	underestimated	the	increases	in	MPO,	as	quan‐
titative	ELISA	revealed	that	absolute	MPO	levels	actually	increased	
nearly 10‐fold in episodic vs	remission	plasma	(Figure	2B).	Thus,	we	
conclude that a) hemoconcentration alone could not account for ele‐
vations in circulating concentration of plasma proteins; b) changes in 
plasma protein levels are not solely based extravasation due to size.
The impetus for neutrophil activation is still unknown. Because 
many patients have infections preceding flares and most have ele‐
vated serum levels of pro‐inflammatory cytokines at the onset of an 
attack, the factors inciting neutrophil activation may not be unique 
to	SCLS.	Neutrophil	degranulation	occurs	in	other	diseases	associated	
with	systemic	inflammation	including	sepsis.	Notably,	however,	mean	
plasma	levels	of	azurophilic	granule	components	such	as	MPO	in	acute	
SCLS	were	nearly	ninefold	higher	than	those	in	septic	plasma	(514	vs 
60 ng/mL).15 Similarly, although elevated levels of tertiary granule con‐
stituents	including	MMP9	are	observed	in	sepsis	and	other	systemic	
diseases with prominent vascular abnormalities such as Kawasaki syn‐
drome,	levels	of	MMP9	are	twofold	to	fivefold	higher	in	SCLS.16
Our results thus far suggest that neutrophils from SCLS patients 
are not predisposed to degranulate or become activated in response 
to routine inflammatory mediators. This was somewhat unexpected 
since we discovered distinct transcriptomes and responses of SCLS 
ECs and peripheral blood mononuclear cells compared to healthy 
controls.7,10	For	example,	monocytes	and	ECs	from	SCLS	patients	pro‐
duced more pro‐inflammatory mediators—including adrenomedullin 
(ADM)	and	CXCL10—in	response	to	treatment	with	SCLS‐associated	
cytokines	 (IFNγ) compared to controls.3,10 It is possible that SCLS 
neutrophils may hyper‐respond to a constellation of SCLS‐associated 
factors that cannot be fully recapitulated in vitro; limited sample avail‐
ability precludes us from formally testing this hypothesis at the present 
time through studies of matched patient neutrophils and acute sera.
Clinical manifestations of acute SCLS including hypovolemic 
shock and anasarca most likely result from disruption of the endo‐
thelial barrier of the soft tissue microvasculature.2 The current study 
suggests that neutrophil‐derived mediators contribute to endothe‐
lial	 dysfunction	 in	 SCLS.	MPO	 is	 a	phagocytic	 peroxidase	enzyme	
whose major product is hypochlorous acid, a potent microbicidal 
agent,	generated	from	hydrogen	peroxide	(H2O2), which plays a key 
role in host responses.17	MPO	and	ROS	including	H2O2 have been 
shown	 to	 increase	 permeability	 of	 HMVEC	monolayers	 in	 vitro.18 
In	 addition,	MPO	has	 the	 capacity	 to	 sequester	 nitric	 oxide	 (NO),	
F I G U R E  4  Acute	systemic	capillary	leak	syndrome	(SCLS)	
sera	elicit	neutrophil	activation.	(A‐C),	Purified	neutrophils	from	
healthy donors were left untreated or incubated with acute or 
remission SCLS sera for one hour followed by immunostaining with 
antibodies against the indicated surface markers and analysis by 
flow cytometry. Results are expressed as the fold change in the 
percentage of cells positive for the indicated markers relative to 
unstimulated	cells;	*P	=	0.04,	**P	=	0.002,	Mann‐Whitney	u test
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resulting	 in	 decreased	 bioavailability.	 NO	 promotes	 relaxation	 of	
vascular smooth muscle and endothelial contraction and has been 
implicated as a therapeutic target for SCLS‐associated hypoten‐
sion.19	Rodent	studies	show	that	MPO	localizes	at	the	vascular	en‐
dothelium and extracellular matrix under inflammatory stress and 
affects vascular smooth muscle and endothelial functions.20 ROS 
may also induce EC apoptosis; however, we did not observe apop‐
tosis	of	HMVECs	incubated	with	acute	or	convalescent	SCLS	sera.2
Another	 key	 finding	 is	 the	 increased	 activation	 of	 neutrophils	
induced by acute but not basal sera, as indicated by the increased 
percentage	 of	 the	 cells	 shedding	 CD62L.	 A	 CD16bright/CD62Ldim 
neutrophil subset appears to be quite distinct from other neutrophil 
subpopulations in vivo; published work has suggested that such cells 
may be recruited from bone marrow to circulation in response to 
acute inflammation.13 This subset is less adherent to ECs and may 
play an immunosuppressive function as it preferentially migrates to 
splenic white pulp and inhibits T cell proliferation.12,21	Whether	this	
neutrophil subpopulation has a distinct function in SCLS or simply 
reflects de novo activation requires further study.
In summary, through multiplexed proteomic screening of plasma, 
we have discerned a panoply of proteins enriched in plasma during 
F I G U R E  5  Activated	neutrophil	supernatants	enhance	endothelial	permeability.	(A‐B),	Transendothelial	resistance	(TER)	across	Blood	
outgrowth endothelial cells from healthy subjects or systemic capillary leak syndrome (SCLS) patients was measured after application of 
fMLP‐stimulated	neutrophil	supernatants	for	30	minutes	(A)	or	15	hours	(B).	TER	over	time	in	a	representative	experiment	is	shown	on	the	
left;	bar	graphs	on	right	show	the	percentage	decrease	in	baseline	resistance	at	the	indicated	time	points	(mean	±	SEM)
F I G U R E  6  SOMAscan	and	other	discovery‐driven	approaches	
to unraveling systemic capillary leak syndrome (SCLS) disease 
mechanisms.	Analysis	of	shared	genes	encoding	proteins	increased	
greater than twofold in acute vs remission SCLS plasma and 
transcripts significantly enriched >log2‐fold in SCLS Blood‐
outgrowth endothelial cells vs controls using GeneVenn. Shared 
genes listed at bottom
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SCLS flares that suggests widespread neutrophil activation/degranu‐
lation.	Our	results	demonstrate	the	utility	of	SOMAscan	as	a	discovery	
tool	for	disease	mechanisms.	A	comparison	of	genes	encoding	proteins	
elevated in acute SCLS plasma with transcripts overexpressed SCLS 
ECs	compared	to	controls	(unpublished	RNA‐Seq	data)	revealed	a	pos‐
sible	cellular	source	for	several	SCLS‐enriched	proteins	(Figure	6).	As	
but one example, platelet‐derived growth factor B, which is secreted 
by ECs, stimulates proliferation and activation of pericytes, which are 
smooth muscle‐like cells surrounding microvessels. Pericyte cover‐
age is required for maintenance of microvascular endothelial barrier 
function in acute inflammation.22	We	believe	that	these	and	other	dis‐
covery‐driven approaches will eventually lead to advances in classifi‐
cation of SCLS and development of biomarkers for treatment efficacy.
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